MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Recursion Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

5.52 4.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.25

Max

5.56

Belangrijke statistieken

By Trading Economics

Inkomsten

31M

-172M

Verkoop

4.4M

19M

Winstmarge

-899.843

Werknemers

800

EBITDA

44M

-148M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+11.84% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-101M

2.4B

Vorige openingsprijs

1.37

Vorige sluitingsprijs

5.52

Nieuwssentiment

By Acuity

50%

50%

172 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 okt 2025, 21:07 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 okt 2025, 17:03 UTC

Belangrijke Marktbewegers

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 okt 2025, 23:53 UTC

Marktinformatie

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 okt 2025, 23:39 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 okt 2025, 22:15 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 22:15 UTC

Marktinformatie

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 okt 2025, 21:57 UTC

Acquisities, Fusies, Overnames

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 okt 2025, 21:36 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 21:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 okt 2025, 21:36 UTC

Marktinformatie

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 okt 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 okt 2025, 21:06 UTC

Acquisities, Fusies, Overnames

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 okt 2025, 20:52 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 okt 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

13 okt 2025, 20:35 UTC

Acquisities, Fusies, Overnames

Goldman Expects to Close Deal in 1Q

13 okt 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 okt 2025, 20:33 UTC

Acquisities, Fusies, Overnames

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 okt 2025, 20:32 UTC

Acquisities, Fusies, Overnames

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 okt 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 okt 2025, 20:29 UTC

Acquisities, Fusies, Overnames

Goldman Sachs to Buy VC Firm Industry Ventures

13 okt 2025, 19:05 UTC

Marktinformatie

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 okt 2025, 18:59 UTC

Marktinformatie

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 okt 2025, 18:26 UTC

Marktinformatie

Precious Metals Close at New Record Highs -- Market Talk

13 okt 2025, 18:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 18:10 UTC

Marktinformatie

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 okt 2025, 17:05 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 okt 2025, 17:05 UTC

Marktinformatie

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 okt 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 okt 2025, 15:35 UTC

Marktinformatie

Precious Metals Push Record Highs Further -- Market Talk

Peer Vergelijking

Prijswijziging

Recursion Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

11.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.95 USD  11.84%

Hoogste 8 USD

Laagste 3 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Recursion Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

1

Buy

4

Hold

0

Sell

Technische score

By Trading Central

4.15 / 4.75Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

172 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat